[Management of myelodysplastic syndromes]

Abstract

Myelodysplastic syndromes are heterogeneous diseases whose molecular characteristics have only been identified in recent years. Better identification of prognostic factors, larger access to allogeneic stem cell transplantation and the advent of new drugs notably hypomethylating agents (azacitidine, decitabine) and lenalidomide have improved patient outcome.

Keywords: Caractérisation; Characterization; Cytogenetic; Cytogénétique; Molecular; Moléculaire; Myelodysplastic syndrome; Syndromes myélodysplasiques; Traitement; Treatment.